Skip to content

Moderna Says Covid Shot for Younger Kids Showed Strong Results

  • Biotech preparing to ask U.S., EU regulators for clearance
  • Children ages 6 through 11 developed strong immune response
New Vaccinations Are Rebounding in the U.S. Covid Hot Spots
Photographer: Angus Mordant/Bloomberg
Updated on

Moderna Inc. said that its Covid-19 vaccine showed a strong immune response in younger children in a late-stage clinical trial, paving the way for submission to regulators for clearance in those age 6 to under 12. 

An interim analysis showed a protective antibody response from children in the study, Cambridge, Massachusetts-based Moderna said Monday in a statement. Participants received two 50 microgram doses -- half that initially given to adults -- spaced 28 days apart.